课题基金 / 基金详情

项目摘要

项目成果

Steffi Oesterreich的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We originally cloned SAFB1 as a transcriptional repressor, and it has since been implicated in a number of processes including hormone response, and transformation. The SAFB1 gene shows extremely high rates of loss of heterozygosity in breast cancer, and its loss is associated with high grade tumors, and reduced survival of breast cancer patients. Structure-function studies identified a transcriptional repression domain and overexpression of SAFB1 blunted estrogen-induction of gene expression and enhanced estrogen-mediated repression. Intriguingly, we found that sumoylation of SAFB1 was necessary for its co-repressor activity. We generated SAFB1-null mice which showed pre- and neonatal lethality, with surviving mice having dramatic defects in the reproductive system. To gain more insight into SAFB1's role in ER1 action, we performed an unbiased screen using SAFB1 siRNA knockdown followed by microarray analysis of estrogen-stimulated breast cancer cells. This experiment revealed a significant role for SAFB1 in estrogen-mediated repression of gene expression, and candidate genes were identified that showed a complete requirement for SAFB1 in estrogen-mediated downregulation. These candidates include proteins known to be involved in migration, invasion, and survival, such as NEDD9 and osteoprotegerin (OPG). Furthermore, we identified a novel role for HDAC7 in estrogen-mediated repression of some of the same candidate genes. We thus hypothesize that SAFB1 is an important and unique co-regulator that is critical for estrogen downregulation of genes, and that the repression is mediated through its posttranslational modification by sumoylation and, at least in part, through interaction with HDAC7. Finally, we hypothesize that SAFB1-mediated repression of its target genes is critical for its role in breast tumorigenesis, since loss of repression might result in increased migration, invasion, and survival of breast cancer cells. We will test these hypotheses by analyzing how SAFB1 mediates transcriptional repression of estrogen-responsive target genes, how is its co-repressor function modified by posttranslational modification, and we will test whether repression of its target genes contributes to SAFB1's role in breast tumorigenesis? This work is highly significant since it will provide insight into fundamental mechanisms of SAFB1 action which may contribute to a change in the paradigm of ER1 action. While ER1 has mainly been studied as a transcriptional activator, the equally frequent estrogen-mediated repression of gene expression, and in particular the role of co-repressors like SAFB1 in this repression, is an understudied area. Most importantly, we will also learn whether and how this repression activity of SAFB1 is critical for its role in breast tumorigenesis. PUBLIC HEALTH RELEVANCE: SAFB1 is a transcriptional co-repressor, and it has since been implicated in a number of cellular processes including hormone, response, immortalization, apoptosis, and transformation. We have discovered that SAFB1 plays a significant role in estrogen- mediated repression of gene expression, which is an understudied yet critical process in estrogen receptor action. Here we propose to study the in-depth mechanism of this repression, and how this relates to SAFB1's role in breast tumorigenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2019 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar
  • 批准号:
    9760128
  • 项目类别:
  • 资助金额:
    $0.7万
  • 财政年份:
    2019
  • 负责人:
    Steffi Oesterreich
  • 依托单位:
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer
FGFR4: A druggable mediator of endocrine resistance in breast cancer
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: